Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study.

abstract：BACKGROUND:Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with a pharmacokinetic profile supporting once-daily dosing, and potent in-vitro activity against the most common NNRTI-resistant HIV-1 variants. We compared doravirine with ritonavir-boosted darunavir, when both were given with two...

journal_title：The lancet. HIV

authors： Molina JM,Squires K,Sax PE,Cahn P,Lombaard J,DeJesus E,Lai MT,Xu X,Rodgers A,Lupinacci L,Kumar S,Sklar P,Nguyen BY,Hanna GJ,Hwang C,DRIVE-FORWARD Study Group.

更新日期：2018-05-01 00:00:00

abstract：BACKGROUND:The HIV epidemic in the population of Nairobi as a whole is in decline, but a concentrated sub-epidemic persists in key populations. We aimed to identify an optimal portfolio of interventions to reduce HIV incidence for a given budget and to identify the circumstances in which pre-exposure prophylaxis (PrEP)...

journal_title：The lancet. HIV

authors： Cremin I,McKinnon L,Kimani J,Cherutich P,Gakii G,Muriuki F,Kripke K,Hecht R,Kiragu M,Smith J,Hinsley W,Gelmon L,Hallett TB

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:Modest efficacy was reported for the HIV vaccine tested in the RV144 trial, which comprised a canarypox vector (ALVAC) and envelope (env) glycoprotein (gp120). These vaccine components were adapted to express HIV-1 antigens from strains circulating in South Africa, and the adjuvant was changed to increase im...

journal_title：The lancet. HIV

authors： Bekker LG,Moodie Z,Grunenberg N,Laher F,Tomaras GD,Cohen KW,Allen M,Malahleha M,Mngadi K,Daniels B,Innes C,Bentley C,Frahm N,Morris DE,Morris L,Mkhize NN,Montefiori DC,Sarzotti-Kelsoe M,Grant S,Yu C,Mehra VL,Pen

更新日期：2018-07-01 00:00:00

abstract：BACKGROUND:ADVANCE compared the efficacy and safety of two antiretroviral first-line combinations (dolutegravir combined with emtricitabine and either tenofovir disoproxil fumarate or tenofovir alafenamide), with a third regimen (efavirenz combined with emtricitabine and tenofovir disoproxil fumarate) previously recomm...

journal_title：The lancet. HIV

authors： Venter WDF,Sokhela S,Simmons B,Moorhouse M,Fairlie L,Mashabane N,Serenata C,Akpomiemie G,Masenya M,Qavi A,Chandiwana N,McCann K,Norris S,Chersich M,Maartens G,Lalla-Edward S,Vos A,Clayden P,Abrams E,Arulappan N,Hi

更新日期：2020-10-01 00:00:00

abstract：:Novel diagnostic technologies, including nanotechnology, microfluidics, -omics science, next-generation sequencing, genomics big data, and machine learning, could contribute to meeting the UNAIDS 95-95-95 targets to end the HIV epidemic by 2030. Novel technologies include multiplexed technologies (including biomarker-...

journal_title：The lancet. HIV

authors： Pai NP,Karellis A,Kim J,Peter T

更新日期：2020-08-01 00:00:00

abstract：BACKGROUND:Standard approaches to estimation of losses in the HIV cascade of care are typically cross-sectional and do not include the population stages before linkage to clinical care. We used indiviual-level longitudinal cascade data, transition by transition, including population stages, both to identify the health-...

journal_title：The lancet. HIV

authors： Haber N,Tanser F,Bor J,Naidu K,Mutevedzi T,Herbst K,Porter K,Pillay D,Bärnighausen T

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:The number of people on antiretroviral therapy (ART) requiring treatment monitoring in low-resource settings is rapidly increasing. Point-of-care (POC) testing for ART monitoring might alleviate burden on centralised laboratories and improve clinical outcomes, but its cost-effectiveness is unknown. METHODS:...

journal_title：The lancet. HIV

authors： Sharma M,Mudimu E,Simeon K,Bershteyn A,Dorward J,Violette LR,Akullian A,Abdool Karim SS,Celum C,Garrett N,Drain PK

更新日期：2020-12-18 00:00:00

abstract：BACKGROUND:An intravaginal ring that releases the tenofovir prodrug, tenofovir disoproxil fumarate, provided 100% protection in macaques against simian HIV and was safe in a 14-day clinical trial in sexually abstinent women. We aimed to assess the safety and pharmacokinetics of this intravaginal ring over 90 days in se...

journal_title：The lancet. HIV

authors： Keller MJ,Wood L,Billingsley JM,Ray LL,Goymer J,Sinclair S,McGinn AP,Marzinke MA,Frank B,Srinivasan S,Liu C,Atrio JM,Espinoza L,Mugo N,Spiegel HML,Anderson PL,Fredricks DN,Hendrix CW,Marrazzo J,Bosinger SE,Herold

更新日期：2019-08-01 00:00:00

abstract：BACKGROUND:Although antiretroviral regimens containing integrase inhibitors rapidly suppress HIV viral load in non-pregnant adults, few published data from randomised controlled trials have compared the safety and efficacy of any integrase inhibitor to efavirenz when initiated during pregnancy. We compared safety and e...

journal_title：The lancet. HIV

authors： João EC,Morrison RL,Shapiro DE,Chakhtoura N,Gouvèa MIS,de Lourdes B Teixeira M,Fuller TL,Mmbaga BT,Ngocho JS,Njau BN,Violari A,Mathiba R,Essack Z,Pilotto JHS,Moreira LF,Rolon MJ,Cahn P,Prommas S,Cressey TR,Chokephai

更新日期：2020-05-01 00:00:00

abstract：BACKGROUND:Tuberculosis, which is often undiagnosed, is the major cause of death among HIV-positive people. We aimed to test whether the use of a clinical algorithm enabling the initiation of empirical tuberculosis treatment by nurses in primary health-care clinics would reduce mortality compared with standard of care ...

journal_title：The lancet. HIV

authors： Grant AD,Charalambous S,Tlali M,Karat AS,Dorman SE,Hoffmann CJ,Johnson S,Vassall A,Churchyard GJ,Fielding KL

更新日期：2020-01-01 00:00:00

abstract：:South Africa intends to include dolutegravir in its first-line antiretroviral therapy (ART) regimen because of cost savings, the drug's high barrier to resistance, and efficacy. However, recent data from Botswana suggest potential teratogenicity of dolutegravir. WHO recommends that non-pregnant women of childbearing a...

journal_title：The lancet. HIV

authors： Black V,Schwartz SR

更新日期：2018-12-01 00:00:00

abstract：BACKGROUND:With continued roll-out of antiretroviral therapy (ART) in resource-limited settings, evidence is emerging of increasing levels of transmitted drug-resistant HIV. We aimed to compare the effectiveness and cost-effectiveness of different potential public health responses to substantial levels of transmitted d...

journal_title：The lancet. HIV

authors： Phillips AN,Cambiano V,Miners A,Revill P,Pillay D,Lundgren JD,Bennett D,Raizes E,Nakagawa F,De Luca A,Vitoria M,Barcarolo J,Perriens J,Jordan MR,Bertagnolio S

更新日期：2014-11-01 00:00:00

abstract：BACKGROUND:As HIV incidence and mortality continue to increase in eastern Europe and central Asia, particularly among people who inject drugs (PWID), it is crucial to effectively scale-up opioid agonist therapy (OAT), such as methadone or buprenorphine maintenance therapy, to optimise HIV outcomes. With low OAT coverag...

journal_title：The lancet. HIV

authors： Tan J,Altice FL,Madden LM,Zelenev A

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:As access to antiretroviral therapy (ART) expands, increasing numbers of older patients will start treatment and need specialised long-term care. However, the effect of age in ART programmes in resource-constrained settings is poorly understood. The HIV epidemic is ageing rapidly and South Africa has one of ...

journal_title：The lancet. HIV

authors： Cornell M,Johnson LF,Schomaker M,Tanser F,Maskew M,Wood R,Prozesky H,Giddy J,Stinson K,Egger M,Boulle A,Myer L,International Epidemiologic Databases to Evaluate AIDS-Southern Africa Collaboration.

更新日期：2015-09-01 00:00:00

abstract：BACKGROUND:WHO-recommended second-line antiretroviral therapy (ART) of a pharmacologically enhanced (boosted) protease inhibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs) might be compromised by resistance. Results of the 96 week SECOND-LINE randomised trial showed that NtRTI-sparing ART w...

journal_title：The lancet. HIV

authors： Boyd MA,Moore CL,Molina JM,Wood R,Madero JS,Wolff M,Ruxrungtham K,Losso M,Renjifo B,Teppler H,Kelleher AD,Amin J,Emery S,Cooper DA,SECOND-LINE study group.

更新日期：2015-02-01 00:00:00

abstract：BACKGROUND:HIV testing is the important entry point for HIV care and prevention service, but uptake of HIV testing and thus coverage of antiretroviral therapy are much lower in older children and adolescents than in adults. We investigated the effect of economic incentives provided to caregivers of children aged 8-17 y...

journal_title：The lancet. HIV

authors： Kranzer K,Simms V,Bandason T,Dauya E,McHugh G,Munyati S,Chonzi P,Dakshina S,Mujuru H,Weiss HA,Ferrand RA

更新日期：2018-02-01 00:00:00

abstract：BACKGROUND:In patients with HIV, immune reconstitution after antiretroviral therapy (ART) is often incomplete. We assessed the probability of patients reaching a CD4/CD8 ratio of 1 or more after the start of ART and its association with the onset of non-AIDS-defining events and death. METHODS:We did an analysis of the...

journal_title：The lancet. HIV

authors： Mussini C,Lorenzini P,Cozzi-Lepri A,Lapadula G,Marchetti G,Nicastri E,Cingolani A,Lichtner M,Antinori A,Gori A,d'Arminio Monforte A,Icona Foundation Study Group.

更新日期：2015-03-01 00:00:00

abstract：BACKGROUND:As pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine for the prevention of HIV infection is rolled out internationally, strategies to maintain effectiveness and to minimise adverse effects merit consideration. In this study, we aimed to assess reductions in renal function a...

journal_title：The lancet. HIV

authors： Gandhi M,Glidden DV,Mayer K,Schechter M,Buchbinder S,Grinsztejn B,Hosek S,Casapia M,Guanira J,Bekker LG,Louie A,Horng H,Benet LZ,Liu A,Grant RM

更新日期：2016-11-01 00:00:00

abstract：BACKGROUND:Measures of CD4 T-cell count and HIV-1 plasma viral load before antiretroviral therapy are proxies for virulence. Whether these proxies are changing over time has implications for prevention and treatment. The aim of this study was to investigate those trends. METHODS:Data were derived from the Concerted Ac...

journal_title：The lancet. HIV

authors： Pantazis N,Porter K,Costagliola D,De Luca A,Ghosn J,Guiguet M,Johnson AM,Kelleher AD,Morrison C,Thiebaut R,Wittkop L,Touloumi G,CASCADE Collaboration in EuroCoord.

更新日期：2014-12-01 00:00:00

abstract：BACKGROUND:All recent treatment guidelines recommend integrase strand transfer inhibitors (INSTIs) as components of initial HIV therapy. Bictegravir, a novel, once-daily, unboosted INSTI, showed potent activity in a 10 day monotherapy study and has a high in-vitro resistance barrier. On the basis of these results, we d...

journal_title：The lancet. HIV

authors： Sax PE,DeJesus E,Crofoot G,Ward D,Benson P,Dretler R,Mills A,Brinson C,Peloquin J,Wei X,White K,Cheng A,Martin H,Quirk E

更新日期：2017-04-01 00:00:00

abstract：BACKGROUND:Incarceration provides an opportunity for engagement in HIV care but is associated with poor HIV treatment outcomes after release. We aimed to assess post-release linkage to HIV care (LTC) and the effect of transitional case management services. METHODS:To create a retrospective cohort of all adults with HI...

journal_title：The lancet. HIV

authors： Loeliger KB,Altice FL,Desai MM,Ciarleglio MM,Gallagher C,Meyer JP

更新日期：2018-02-01 00:00:00

abstract：BACKGROUND:Universal antiretroviral therapy (ART), as per the 2015 WHO recommendations, might reduce population HIV incidence. We investigated the effect of universal test and treat on HIV acquisition at population level in a high prevalence rural region of South Africa. METHODS:We did a phase 4, open-label, cluster r...

journal_title：The lancet. HIV

authors： Iwuji CC,Orne-Gliemann J,Larmarange J,Balestre E,Thiebaut R,Tanser F,Okesola N,Makowa T,Dreyer J,Herbst K,McGrath N,Bärnighausen T,Boyer S,De Oliveira T,Rekacewicz C,Bazin B,Newell ML,Pillay D,Dabis F,ANRS 12249 Tas

更新日期：2018-03-01 00:00:00

abstract：BACKGROUND:Isoniazid preventive therapy prevents active tuberculosis in people with HIV, but previous studies have found no evidence of benefit in people with HIV who had a negative tuberculin skin test, and a non-significant effect on mortality. We aimed to estimate the effect of isoniazid preventive therapy given wit...

journal_title：The lancet. HIV

authors： Ross JM,Badje A,Rangaka MX,Walker AS,Shapiro AE,Thomas KK,Anglaret X,Eholie S,Gabillard D,Boulle A,Maartens G,Wilkinson RJ,Ford N,Golub JE,Williams BG,Barnabas RV

更新日期：2021-01-01 00:00:00

abstract：:The evaluation of immune-based approaches to achieve an antiretroviral therapy free remission of HIV infection requires proven efficacy through antiretroviral therapy interruption placebo-controlled trials. This approach is not without risk to participants and innovative trial designs need to be developed that minimis...

journal_title：The lancet. HIV

authors： Moore CL,Stöhr W,Crook AM,Richert L,Leliévre JD,Pantaleo G,García F,Vella S,Lévy Y,Thiébaut R,McCormack S

更新日期：2019-05-01 00:00:00

abstract：BACKGROUND:The South African national HIV plan recommends pre-exposure prophylaxis (PrEP) for transgender women, whose HIV prevalence estimates are as high as 25% in sub-Saharan Africa. The aim of this study was to explore PrEP awareness, uptake, and willingness, as well as associated barriers and facilitators, in orde...

journal_title：The lancet. HIV

authors： Poteat T,Malik M,van der Merwe LLA,Cloete A,Adams D,Nonyane BAS,Wirtz AL

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:In high HIV burden settings, maximising the coverage of prevention strategies is crucial to achieving epidemic control. However, little is known about the reach and effect of these strategies in some communities. METHODS:We did a cross-sectional community survey in the adjacent Greater Edendale and Vulindle...

journal_title：The lancet. HIV

authors： Kharsany ABM,Cawood C,Khanyile D,Lewis L,Grobler A,Puren A,Govender K,George G,Beckett S,Samsunder N,Madurai S,Toledo C,Chipeta Z,Glenshaw M,Hersey S,Abdool Karim Q

更新日期：2018-08-01 00:00:00

abstract：:Progress in the development and introduction of paediatric formulations for key infectious diseases is poor in low-income and middle-income countries (LMICs). Although major steps have been made in the scale-up of antiretroviral medicines in LMICs, the development and deployment of formulations for infants and childre...

journal_title：The lancet. HIV

authors： Penazzato M,Watkins M,Morin S,Lewis L,Pascual F,Vicari M,Lee J,Hargreaves S,Doherty M,Siberry GK

更新日期：2018-05-01 00:00:00

abstract：BACKGROUND:Switching from therapy based on a boosted protease inhibitor to bictegravir, emtricitabine, and tenofovir alafenamide could avoid drug interactions and unwanted side-effects in virologically suppressed adults with HIV-1 infection, while maintaining a high barrier to resistance and providing a simplified once...

journal_title：The lancet. HIV

authors： Daar ES,DeJesus E,Ruane P,Crofoot G,Oguchi G,Creticos C,Rockstroh JK,Molina JM,Koenig E,Liu YP,Custodio J,Andreatta K,Graham H,Cheng A,Martin H,Quirk E

更新日期：2018-07-01 00:00:00

abstract：BACKGROUND:BMS-663068 is an oral prodrug of BMS-626529, an attachment inhibitor that binds to HIV-1 gp120, blocking viral attachment to host CD4 cells. AI438011 is an ongoing trial investigating the efficacy, safety, and dose-response of BMS-663068 in treatment-experienced, HIV-1-infected patients. Herein we present th...

journal_title：The lancet. HIV

authors： Lalezari JP,Latiff GH,Brinson C,Echevarría J,Treviño-Pérez S,Bogner JR,Thompson M,Fourie J,Sussmann Pena OA,Mendo Urbina FC,Martins M,Diaconescu IG,Stock DA,Joshi SR,Hanna GJ,Lataillade M,AI438011 study team.

更新日期：2015-10-01 00:00:00

abstract：BACKGROUND:Although lifelong combination antiretroviral therapy (ART) is recommended for all individuals with HIV, few data exist for pregnancy outcomes associated with ART initiation before conception. We assessed adverse pregnancy outcomes associated with ART initiated before conception compared with that of ART star...

journal_title：The lancet. HIV

authors： Uthman OA,Nachega JB,Anderson J,Kanters S,Mills EJ,Renaud F,Essajee S,Doherty MC,Mofenson LM

更新日期：2017-01-01 00:00:00